

29 57. (New) The recombinant adenovirus expression vector of claim 50¹⁷, wherein the gene encoding the foreign protein is expressed under control of the adenovirus 2 major late promoter.

25 58. (New) A recombinant adenovirus expression vector, wherein the vector is A/C/N/53.A)

REMARKS

Applicants and the undersigned attorney thank the Examiner for the courtesy of a telephone interview on July 15, 1998. During the interview, the proposed new independent claims were discussed. The Examiner indicated that entry of the new claims should not present a problem provided that Applicants point to proper support in the specification, which Applicants have done herein.

The requested amendments satisfy the requirements for entry of a 37 CFR   1.312(a) amendment as set forth in MPEP   714.16, as follows.

The amendments at pages 19-20 of the specification are necessary to correct an error in the description of Table 1. Specifically, at present, the specification states that "The coding sequence of the p53 gene is set forth below in Table I" (p. 19, lines 7-8). However, inspection of Table 1 on p. 20 reveals that the Table actually sets forth the amino acid sequence encoded by the p53 gene. Moreover, the first line of the amino acid sequence in Table 1 includes amino acids that occur before the initial methionine residue of the p53 polypeptide. That the p53 protein begins with "MEEPQ. . .", and that the nucleotides immediately preceding the codon for this methionine was an untranslated region, was known prior to Applicants' filing date (*see, e.g.,* Buchman *et al.* (1988) *Cell* 70: 245-252). The requested amendment to the specification at page 53 similarly corrects an error in the specification, namely, that the specification contained two tables labeled "Table 1"; the second Table is now correctly numbered as "Table 2". Thus, the requested amendments to the specification are directed to formal matters and require no additional search or examination.

79